Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,143.12 UNCHANGED
Delayed Quote Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? ↗
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus. 
Via The Motley Fool
News headline image
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
From Wall Street Investor
Via GlobeNewswire
News headline image
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield ↗
U.S. healthcare stocks delivered 28.8% gains over one year versus 22.5% for international peers. Both funds carry nearly identical expense ratios and low volatility profiles. 
Via The Motley Fool
Topics ETFs
Eli Lilly (NYSE:LLY) Combines Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
News headline image
2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Headwinds
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock ↗
The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error. 
Via The Motley Fool
News headline image
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled ↗
Eli Lilly is partnering with Ginkgo Bioworks on drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗
Owning a low-cost index fund is one of the simplest ways to build wealth in the stock market over the long term. 
Via The Motley Fool
Topics ETFs Economy Retirement
News headline image
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Here Are My Top 4 Stocks to Buy in October ↗
Get 'em while they're still on sale. Catalysts are on the horizon. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech ↗
Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance. 
Via The Motley Fool
Topics ETFs
News headline image
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB ↗
VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
1 Mid-Cap Stock to Keep an Eye On and 2 We Ignore
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
2 Growth Stocks with All-Star Potential and 1 We Brush Off
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future. 
Via The Motley Fool
News headline image
Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet ↗
Can anyone stop Eli Lilly’s progress in the weight loss market? 
Via The Motley Fool
News headline image
Eli Lilly Just Announced Something Big. Here’s What It Means for Investors. ↗
The company is the leader in a key growth market. 
Via The Motley Fool
News headline image
Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way. ↗
Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care. 
Via The Motley Fool
Topics Economy
News headline image
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗
With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%. 
Via MarketBeat
Topics Bonds Retirement
News headline image
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors ↗
The company's search for its next wave of billion-dollar drugs continues. 
Via The Motley Fool
News headline image
3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗
VHT, BND, and VOO could be your best bets in the next economic downturn. 
Via The Motley Fool
Topics ETFs Economy Regulatory Compliance
News headline image
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
Via AB Newswire
News headline image
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? ↗
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks. 
Via The Motley Fool
News headline image
Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades? ↗
The company is constantly thinking big. 
Via The Motley Fool
News headline image
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗
Could this be what Novo needs to turn things around? 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗
There could be more catalysts for the biotech over the next 18 months. 
Via The Motley Fool
News headline image
2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗
There is probably no dividend cut on the horizon for these healthcare companies. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Emerging Biotech Stocks With Significant Upside Potential ↗
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs. 
Via MarketBeat
Topics Intellectual Property
News headline image
Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug ↗
Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.